Drug Eluting Stent Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Coating Type (Polymer-based Coatings (Non-biodegradable, Biodegradable)), Polymer-free Coatings(Micro porous Surface, Micro structured Surface, Slotted tubular Surface, Nanoporous Surface)), By Application (Coronary Artery Disease, Peripheral Artery Disease), By Region & Competition, 2020-2030F

Market Overview

Global Drug Eluting Stent Market was valued at USD 8.30 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.08% through 2030. The global healthcare industry has witnessed remarkable advancements in recent years, with technology and innovation playing pivotal roles in enhancing patient care and treatment outcomes. Among these innovations, drug-eluting stents (DES) have emerged as a game-changer in the field of interventional cardiology. These tiny, lifesaving devices are transforming the way coronary artery diseases are treated, leading to a substantial growth in the global drug-eluting stent market.

A drug-eluting stent is a medical device designed to treat coronary artery disease (CAD) and prevent the recurrence of blockages in the arteries. It is a tiny mesh tube made of metal that is coated with a special medication, typically an anti-restenotic drug. When implanted in a narrowed or blocked coronary artery, the stent not only serves as a mechanical scaffold to keep the artery open but also releases the drug slowly over time to prevent restenosis, the renarrowing of the artery.

The global drug-eluting stent market has witnessed significant growth in recent years, and several factors are driving this expansion. The rising incidence of coronary artery disease globally is a major driver of the DES market. Lifestyle changes, including sedentary habits and unhealthy diets, have contributed to an increase in CAD cases. Ongoing research and development efforts have led to the introduction of next-generation drug-eluting stents with improved designs, drug formulations, and biodegradable materials, enhancing their efficacy and safety. As the world's population continues to age, the prevalence of CAD is expected to rise. Older individuals are more prone to cardiovascular diseases, creating a growing market for DES. DES procedures are minimally invasive, resulting in shorter recovery times, less pain, and reduced hospital stays compared to traditional open-heart surgeries. This factor is driving patient preference and increasing the adoption of DES. Developing countries are witnessing an increase in healthcare infrastructure and accessibility, which is driving the demand for advanced medical devices like drug-eluting stents.

Key Market Drivers

Aging Global Population

The global aging population is a significant driver of the Drug-Eluting Stent (DES) Market, as elderly individuals are more susceptible to cardiovascular diseases (CVDs), particularly coronary artery disease (CAD). As life expectancy increases worldwide, so does the demand for minimally invasive cardiac interventions, fueling the growth of the DES market. The world’s population is aging rapidly. According to the World Health Organization the global population aged 60 and above is projected to grow from 1 billion in 2020 to 1.4 billion by 2030. By 2050, this demographic will reach 2.1 billion, effectively doubling within three decades. Additionally, the 80+ age group is expected to expand significantly, tripling from its 2020 figure to 426 million by 2050. This rapid demographic shift presents significant implications for industries focused on healthcare, elderly care, and age-related medical solutions, including cardiovascular treatments and drug-eluting stents (DES). Since aging is one of the strongest risk factors for cardiovascular diseases, this demographic shift directly translates into higher demand for interventional cardiology treatments, including drug-eluting stents.

Aging patients often have multiple comorbidities (e.g., diabetes, kidney disease), making open-heart surgeries riskier. Minimally invasive procedures, such as percutaneous coronary intervention (PCI) using drug-eluting stents, offer: Faster recovery times, Lower risk of complications, Reduced hospital stays and medical costs.  These benefits make DES-based procedures the preferred choice for elderly patients, further accelerating market adoption. Governments and private healthcare institutions worldwide are increasing investments in geriatric care and cardiovascular health programs. Higher healthcare budgets are being allocated to manage age-related diseases. Expanded insurance and reimbursement policies are making DES procedures more accessible. Public health initiatives are promoting early detection and treatment of cardiovascular diseases, increasing the number of stent implantations. The U.S. Medicare program covers a significant portion of DES implantation costs for elderly patients. European countries like Germany and France have universal healthcare policies supporting cardiac interventions for senior citizens. These favorable healthcare policies are boosting DES adoption across aging populations.

Rising Prevalence of Cardiovascular Diseases (CVDs)

The increasing global burden of cardiovascular diseases (CVDs) is one of the most significant drivers fueling the growth of the Global Bioresorbable Coronary Stents Market. Cardiovascular diseases (CVDs) remain the leading global cause of mortality, accounting for 17.9 million deaths in 2019, which represents 32% of total global fatalities. Notably, 85% of these deaths resulted from heart attacks and strokes. Furthermore, over 75% of CVD-related deaths occur in low- and middle-income countries, highlighting a critical disparity in healthcare access and cardiac treatment infrastructure. As the number of patients diagnosed with coronary artery disease (CAD) continues to surge, the demand for innovative and effective treatment solutions such as bioresorbable coronary stents (BRS) is rising.  Coronary artery disease, a leading form of CVD, results from the narrowing or blockage of coronary arteries due to atherosclerosis (buildup of plaque). In 2022, the global prevalence of coronary artery disease (CAD) reached 315 million cases, with a 95% uncertainty range of 273 million to 362 million. The age-standardized prevalence rate was recorded at 3,605 cases per 100,000 individuals, with a range of 2,892 to 4,454 per 100,000, underscoring the widespread burden of CAD across diverse populations. The aging global population is a key contributor, as older individuals are more susceptible to CAD. Age remains the most significant nonmodifiable risk factor for coronary artery disease (CAD) and other cardiovascular conditions in older adults. According to the American Heart Association (AHA) 2019 update, 31% of men and 25.4% of women aged 80 and above are diagnosed with CAD, highlighting the increased disease prevalence in aging populations. Rising cases of hypertension, diabetes, and high cholesterol further accelerate the need for effective cardiac interventions. The increasing prevalence of obesity and sedentary lifestyles has exacerbated cardiovascular risks, particularly in developed and developing economies alike. With more patients requiring coronary interventions, bioresorbable stents are emerging as a superior alternative to traditional metallic stents, driving their market growth.

Governments and healthcare organizations worldwide are promoting early diagnosis and preventive care to reduce CVD-related mortality rates. Routine health check-ups and advanced imaging technologies (e.g., CT angiography, stress tests) are leading to the earlier detection of CAD. Patients diagnosed in the early to mid-stages of coronary artery blockage are increasingly being treated with percutaneous coronary intervention (PCI) instead of open-heart surgery. As PCI remains the preferred treatment approach, the adoption of bioresorbable stents is rising due to their ability to provide temporary arterial support while eventually dissolving, restoring normal vascular function. This proactive approach to cardiac care is boosting demand for advanced stent technologies, including bioresorbable coronary stents. Traditional metallic drug-eluting stents (DES), while effective, present long-term complications such as: Late stent thrombosis (blood clot formation around the stent). Chronic inflammation due to the permanent presence of a foreign object. Restricted vascular motion after stent placement. In contrast, bioresorbable coronary stents offer a temporary scaffold that dissolves over time, reducing long-term risks while allowing the artery to regain its natural flexibility. As more cardiologists and healthcare providers recognize these clinical advantages, they are increasingly recommending bioresorbable stents for patients, particularly younger individuals and those at high risk of restenosis.

Favorable Reimbursement Policies

The global drug-eluting stent market has experienced significant growth in recent years, thanks in part to favorable reimbursement policies in various countries. These policies have not only made life-saving treatments more affordable for patients but have also stimulated innovation and investment in the medical device industry. Reimbursement policies play a crucial role in determining the accessibility and affordability of medical treatments, including drug-eluting stents. In many countries, governments and insurance providers have recognized the importance of these devices and have implemented policies to make them more accessible to patients.

Favorable reimbursement policies often result in reduced out-of-pocket expenses for patients. This makes drug-eluting stents more affordable and accessible to a broader range of individuals, ensuring that patients receive the best possible care without incurring significant financial burdens. As reimbursement policies encourage the use of drug-eluting stents, they create a robust market for these devices. This, in turn, incentivizes medical device companies to invest in research and development to create more advanced and effective stents. Continuous innovation benefits both patients and the industry. Favorable reimbursement policies extend the reach of drug-eluting stents to a larger patient population. This expansion of the market can result in increased sales and revenue for medical device manufacturers, which further drives innovation and investment. Medical device companies that produce high-quality drug-eluting stents can gain a competitive advantage in markets with favorable reimbursement policies. This encourages companies to maintain high standards and invest in improving their products. The influence of favorable reimbursement policies is not limited to a single country. As more nations recognize the benefits of these policies, the global drug-eluting stent market continues to grow, creating a positive impact on healthcare infrastructure worldwide.

Download Free Sample Report

Key Market Challenges

Regulatory Hurdles

One of the foremost challenges facing the drug-eluting stent market is the ever-evolving landscape of regulatory requirements. Health authorities in different countries continually update their guidelines and standards for medical devices. Manufacturers must invest substantial resources in research and development to ensure compliance with these evolving regulations. In addition, obtaining approval for new products or modifications can be a time-consuming and expensive process.

Competitive Landscape

The drug-eluting stent market is highly competitive, with several major players dominating the industry. Companies must constantly innovate to stay ahead of the competition and maintain or gain market share. This often involves hefty investments in research and development, clinical trials, and marketing efforts, which can strain company resources.

Pricing Pressures

The cost of drug-eluting stents can be a significant burden for healthcare systems and patients. Payers, including insurance companies and government health agencies, often negotiate aggressively for lower prices, putting pressure on manufacturers to reduce their pricing. This can impact profitability and limit the funds available for research and development.

Key Market Trends

Technological Advancements

The global healthcare industry is experiencing a significant transformation fueled by technological advancements. One area where these advancements are making a profound impact is in the field of interventional cardiology, particularly with drug-eluting stents (DES). DES have revolutionized the treatment of coronary artery disease, and as technology continues to advance, the global drug-eluting stent market is poised for remarkable growth.

One of the significant technological advancements in DES is the development of biocompatible polymers. These polymers improve drug release kinetics and reduce the risk of inflammation and allergic reactions in patients. New-generation DES employ advanced polymers that break down more naturally within the body, reducing long-term complications. Bioabsorbable stents represent a groundbreaking innovation. These stents are designed to gradually dissolve within the body over time, leaving behind a healthier, more natural artery. This technology eliminates some of the long-term limitations associated with traditional metal stents, such as the potential for late-stage thrombosis.

Continuous research and development efforts have led to the discovery of more effective drugs to coat DES. These new drug formulations enhance the stent's efficacy while minimizing side effects. Customized drug delivery systems are also being explored, tailoring treatment to individual patient needs. Advancements in catheter technology have made stent deployment safer and more precise. Miniaturization and enhanced imaging capabilities help interventional cardiologists navigate complex coronary anatomy with greater confidence.

As technology advances, the production of DES becomes more efficient. This often leads to cost savings, making these devices more affordable for healthcare systems and patients alike. Technological advancements have enabled better distribution and accessibility of DES in emerging markets, helping to address the growing burden of cardiovascular disease worldwide.

Segmental Insights

Coating Type Insights

Based on the coating type, the Polymer-based Coatings segment emerged as the fastest growing segment in the global market for Drug Eluting Stent in 2024. Polymer-based coatings have been widely used in drug-eluting stents because they provide excellent control over the release of drugs. These coatings can be engineered to release drugs in a controlled and sustained manner over an extended period. This is crucial for ensuring that the drug remains effective in inhibiting the growth of neointimal tissue (restenosis) around the stent for an extended period. Polymer-based DES have demonstrated significant success in reducing restenosis rates compared to bare-metal stents. By effectively delivering drugs to the target site, polymer-based coatings help inhibit the proliferation of smooth muscle cells and reduce the risk of restenosis. This positive clinical outcome has contributed to the widespread adoption of polymer-based DES. Polymer coatings allow for customization of drug release profiles. Physicians and device manufacturers can choose specific polymers and drug combinations to tailor the DES to the patient's needs. This customization ensures that the stent can effectively address different patient conditions and anatomical variations. Polymer-based coatings can accommodate a variety of drug compounds, including antiproliferative agents, anti-inflammatory drugs, and anti-thrombotic agents. This versatility allows for the development of DES that can address multiple aspects of vascular healing and reduce complications.

Download Free Sample Report

Regional Insights

North America emerged as the largest market in the global Drug Eluting Stent market in 2024, holding the largest market share in terms of value. North America, particularly the United States, is a hub for medical research and innovation. It is home to numerous medical device companies and research institutions that continuously develop and improve drug-eluting stent technologies. These innovations often lead to the introduction of new and advanced products into the market, attracting both domestic and international consumers. The North American region boasts a well-developed and highly advanced healthcare infrastructure, including hospitals, clinics, and specialized medical facilities. This extensive network ensures that patients have access to cutting-edge medical treatments, including drug-eluting stents. The well-established healthcare system plays a significant role in driving demand for these devices. Cardiovascular diseases, such as coronary artery disease, are widespread in North America. These conditions often necessitate the use of drug-eluting stents to treat narrowed or blocked arteries. The high prevalence of these diseases leads to a substantial demand for drug-eluting stents in the region.

Recent Developments

• In March 2024, Boston Scientific has secured FDA approval for its Agent™ Paclitaxel-Coated Balloon Catheter, specifically designed for treating coronary in-stent restenosis (ISR) in patients with coronary artery disease (CAD). This drug-coated balloon (DCB) offers an alternative to traditional balloon angioplasty, additional stent placement, or intracoronary radiation therapy, aiming to mitigate restenosis risk and enhance long-term vessel patency without requiring permanent implants.
• In October 2023, Medinol has received FDA approval for its Elunir-Perl™ Drug-Eluting Stent (DES), expanding its Elunir DES product portfolio for the treatment of coronary artery disease (CAD). The Elunir-Perl features four radiopaque markers two at each end of the stent along with a hybrid polymer-metal radiopaque catheter tip, enhancing precision in stent placement and visibility under fluoroscopy. 

Key Market Players

• Abbott Laboratories ltd.
• Boston Scientific Corporation
• Terumo Corporation
• Medtronic plc
• Biosensors International Ltd
• Cook Medical pvt ltd.
• B. Braun Medical (India) Private Limited
• Biotronik, Inc.
• Lepu Medical Technology Inc.

Report Scope:

In this report, the Global Drug Eluting Stent Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Drug Eluting Stent Market, By Coating Type:

o   Polymer-based Coatings

o   Polymer-free Coatings

• Drug Eluting Stent Market, By Application:

o   Coronary Artery Disease

o   Peripheral Artery Disease

• Drug Eluting Stent Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Drug Eluting Stent Market.

Available Customizations:

Global Drug Eluting Stent market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).